A composition and method for chlorine dioxide production through reaction-diffusion chemistry that facilitates the in situ generation of chlorine dioxide, wherein a dry solid composition of hydroxymethanesulfinic acid monosodium salt dihydrate (abbreviated HMS) and a chlorine dioxide precursor are activated via the addition or absorption of water to produce chlorine dioxide. The dry solid chemical composition comprises dry, safe, transportable reagents that integrate with polymeric materials such as packaging and superabsorbent and stimuli-responsive hydrogel polymers to combine with water to produce chlorine dioxide.

Glass-based particles of a biocompatible material which comprises 40 to about 80 wt % borate (B.sub.2O.sub.3) intermixed into a carrier which is an ointment, cream, or surgical glue.

The present disclosure is directed to devices and systems for oxygenating encapsulated cells. The disclosure further relates to individual components of these devices and systems and methods of using the devices and systems to deliver a therapeutic agent to a subject in need thereof.

The present disclosure provides matrix compositions comprising bioactive glass and methods for treating a defect in tissue demonstrating volumetric tissue loss arising from injury or congenital defect.

An entirely or partially implantable medical product with a negatively charged surface for repulsing bacteria has a superficially bonded substance with a permanently negative excess charge, which substance is inert against cells of the human body and the bacteria contained therein.

The present invention relates to the use of zinc treated precipitated calcium carbonate (PCC), which is obtained by slaking calcium oxide with water to obtain a calcium hydroxide slurry, carbonating the calcium hydroxide slurry, and adding a Zn.sup.2+ ion provider before and/or during the carbonation, in hygienic products, to the hygienic products comprising said zinc treated precipitated calcium carbonate as well as to a process for the preparation of such hygienic products.

Systems, devices, methods, and compositions are described for providing an actively controllable implant configured to, for example, monitor, treat, or prevent microbial growth or adherence to the implant.

Fibrin Sealant products are used for topical hemostasis and tissue adherence. They are composed of two main reagents, fibrinogen and thrombin. When mixed in solution fibrinogen is converted to fibrin upon the addition of activated thrombin. Therefore typically these two components are stored separately in a lyophilized or liquid state, and mixed, upon or immediately before, application to a patient. While effective, these products require significant preparation that must take place immediately before application, thus delaying treatment and limiting the use of these haemostatic products to the treatment of mild forms of low pressure and low volume bleeding. Attempts to eliminate this delay and expand the usefulness and effectiveness of these products have resulted in products produced by processes that require the separation of these components and their deposition in distinct layers within the product. The processes described herein permit the mixing of fibrinogen and thrombin during product manufacture, without excessive fibrin formation. The resulting pre-mixed fibrin sealant material can then be stored in either a frozen or dried state, or suspended in a non-aqueous environment. Activation of the material to form therapeutic fibrin sealant is accomplished by permitting the product to thaw (if frozen) or by the addition of water or other aqueous fluid, including blood, or other bodily fluids, if dried or suspended in a non-aqueous environment. The resulting material can be used to make a product in which a pre-mixed form of activatable fibrin sealant is a desired component.

Bioactive porous bone graft implants in various forms suitable for use in bone tissue regeneration and/or repair, as well as methods of use are provided. The implants are formed of bioactive glass and have an engineered porosity. The implants may be contained in polymer for enhanced clinical results and better handling.

An absorbent article 100 includes an absorber 10, the absorber contains water-absorbent resin particle 10a composed of a deodorant composition, and the deodorant composition contains silver zeolite, a sulfur compound, and a water-absorbent resin.